--Must See--

Bioinformatics Summer Internship 2024 With Hands-On-Training + Project / Dissertation - 30 Days, 3 Months & 6 Months Duration

Bharat Biotech, a leading Indian Biotechnology Company has, through a press release today, announced that its vaccination for Chikungunya (an infection caused the virus CHIKV), is underway for the evaluation of its safety, tolerability, and immunogenicity through Human Trials.

The company has previously produced economical and powerful vaccines for Swine flu. Late last year, it also announced the completion of pre-clinical studies on two Zika virus vaccines developed in-house. Chikungunya has been identified in over 60 countries till date by the WHO, and is transmitted through infected mosquitoes carrying the virus.

The company’s in-house R&D team has now formulated the vaccine for CHIKV using virus isolate from the Indian epidemic. This vaccine was earlier found to be safe and immunogenic during the pre-clinical animal testing and hence has now moved to the next phase of clinical trials.

“Chikungunya is one of the most dreaded viruses in modern times, and developing an efficient vaccine to prevent it means a lot for people at risk of the infection. Our pre-clinical studies were promising and we hope that the first in-human clinical trials successfully meet with the clinical end points.”

States Mr.Krishna Ella, Chairman & MD, Bharat Biotech

The placebo-controlled trial involves 60

healthy volunteers and would test escalating doses of the vaccine in prime-boost regime.

Bharat Biotech filed a patent for CHIKV in 2007, following up with a second patent in 2011. The press release also states that this patent has been granted in the US, Europe, South Africa, and Indonesia.

Source

In search of the perfect burger. Serial eater. In her spare time, practises her "Vader Voice". Passionate about dance. Real Weird.